Evidence map›Paper›PMID 41542685›Full record

ArticlemedRxiv : the preprint server for health sciences2026

ATN Classification and Machine-Learned Plasma Biomarker Phenotypes Reveal Distinct Alzheimer's Pathology in a Population-Based Cohort.

Emmanuel Fle Chea

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Emmanuel Fle CheaIndependent Researcher, University of Minnesota School of Public Health (Alumnus), Minneapolis, MN, USA.ORCID 0009-0005-1563-2558

Funding

HRS Yrs29-34: Y33 SSA CoFundingU01AG009740 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jessica Faul, KENNETH M LANGA · 1990 to 2026
$555.8M
Integrting Information About Aging SurveysR01AG030153 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Sara Adar, Alden L. Gross · 2007 to 2026
$41.7M
NIA NIH HHS R01 AG030153NIA NIH HHS U01 AG009740
6 · The paper itself

Abstract

Background: The ATN (Amyloid/Tau/Neurodegeneration) framework provides a theory-driven approach to Alzheimer's disease (AD) classification using binary biomarker cutoffs, while unsupervised machine learning offers data-driven phenotyping. The concordance between these approaches in population-representative samples remains incompletely characterized. Objective: To compare plasma ATN classification with data-driven clustering methods and evaluate their associations with cognitive outcomes in a nationally representative cohort. Methods: We analyzed plasma biomarkers (Aβ42/40 ratio, p-tau181, NfL, GFAP) from 4,465 participants aged ≥51 years in the Health and Retirement Study 2016 Venous Blood Study. ATN profiles were classified using literature-based cutoffs. We applied k-means clustering, Gaussian mixture modeling, and variational autoencoder (VAE) dimensionality reduction to identify data-driven biomarker-defined subgroups. Agreement between ATN and clustering was quantified using adjusted Rand index (ARI) and normalized mutual information (NMI). Longitudinal analyses examined associations with cognitive decline over 4 years (2016-2020). Results: The analytic sample included 4,465 individuals (mean age 69.7±10.4 years; 58.7% female; 75.8% non-Hispanic White). ATN classification yielded 14 profiles, with A+/T-/N- (27.4%) and A-/T-/N- (22.6%) most prevalent (Figure 2). K-means clustering identified 4 optimal clusters with distinct biomarker signatures. Agreement between ATN and clusters was modest (ARI=0.119, NMI=0.113). Sensitivity analysis excluding GFAP from clustering reduced agreement substantially (ARI=0.03 vs 0.119 with GFAP, -74.5% decrease), demonstrating that GFAP accounts for most of the observed concordance between clustering and ATN classification, with only one-third arising from the shared three biomarkers.[Table S12] Additional sensitivity analyses confirmed that k=4 provides finer biomarker resolution than k=3 by retaining biomarker extreme subgroups[Table S13], and that Cluster 4 represents a stable biological structure across distance metrics[Table S14] despite its small size. Cluster 1 (n=51, 1.2%) showed severe pathology; Cluster 3 (n=3,479, 78.6%) represented the largest and most heterogeneous group, encompassing the broad spectrum of minimal to moderate pathology across all ATN profiles; Cluster 4 (n=14, 0.3%) represented a small but stable non AD biomarker defined subgroup (Jaccard=0.779). The VAE revealed a localized nonlinear structure. Silhouette values in the latent space are not directly comparable to clustering silhouettes, but the VAE embedding showed clearer local separation, whereas PCA explained more variance (67.1%). Both ATN and clusters predicted 4-year cognitive decline (ATN R Conclusions: Theory driven ATN classification and data driven biomarker phenotyping capture partially overlapping but largely distinct information. Modest concordance (ARI=0.119) reflects GFAP's contribution to shared structure, with most alignment arising from GFAP rather than from the three ATN biomarkers alone (ARI=0.03). The primary source of discordance remains the binary versus continuous representation of biomarker variation. Sensitivity analyses showed that k=4 provides finer biomarker resolution than k=3, and that Cluster 4 represents a small but reproducible biomarker defined subgroup. Both approaches predicted cognitive decline with modest effect sizes (R

Indexed as

Alzheimer’s diseaseATN frameworkclusteringcognitive declinemachine learningplasma biomarkerspopulation healthunsupervised learning

Identifiers

PMID41542685
PMCPMC12803393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.